{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:49:57Z","timestamp":1792064997227,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Weight gain and associated adipose tissue remodeling have been partly linked to HIV infection and to some current antiretroviral therapy (ART) regimens in ART-naive and ART-controlled people with HIV (PWH). This review addresses recent findings on adipose tissue distribution and remodeling in PWH, receiving dolutegravir, bictegravir and\/or tenofovir alafenamide (TAF), highlighting how visceral adiposity contributes to cardiometabolic comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Preclinical models exposed to dolutegravir, bictegravir, tenofovir disoproxil fumarate (TDF) and\/or TAF demonstrate alterations in adipose tissue, including mitochondrial dysfunction, fibrosis, inhibited beiging, and insulin resistance. Transcriptomic studies of abdominal subcutaneous fat from ART-controlled PWH further revealed elevated inflammation, fibrosis and insulin resistance. Increased visceral adiposity raises the risk of cardiometabolic disorders such as insulin resistance and diabetes, metabolic-dysfunction-associated steatotic liver disease and cardiovascular diseases. Reversing weight gain linked to ART, by switching regimens or adding antiobesity medications like the GLP-1 receptor agonist semaglutide, has shown potential in reducing adipose tissue remodeling, visceral adiposity and cardiometabolic risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Weight gain and increased visceral adiposity partly driven by some ARTs are associated with higher cardiometabolic risk. HIV and ART can either activate or suppress the fat beiging\/browning phenotype. Reversing weight gain and visceral adiposity in at-risk PWH is a critical clinical goal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coh.0000000000001069","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:03:24Z","timestamp":1790834604000},"page":"480-487","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Weight gain, adipose tissue remodeling and cardiometabolic disease in people with HIV"],"prefix":"10.1097","volume":"21","author":[{"given":"Jennifer","family":"Gorwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"B\u00e9r\u00e9ziat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lagathu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"R1-20261015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41575-023-00867-z","article-title":"Gut microbiota in overweight and obesity: crosstalk with adipose tissue","volume":"21","author":"Cani","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20261015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41591-020-1126-7","article-title":"Brown adipose tissue is associated with cardiometabolic health","volume":"27","author":"Becher","year":"2021","journal-title":"Nat Med"},{"key":"R3-20261015","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R4-20261015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","article-title":"HIV and antiretroviral therapy-related fat alterations","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20261015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/COH.0000000000000674","article-title":"Recent data on adipose tissue, insulin resistance, diabetes and dyslipidaemia in antiretroviral therapy controlled HIV-infected persons","volume":"16","author":"Capeau","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"R6-20261015","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1186\/s12889-023-17137-x","article-title":"Trends in weight change patterns across life course among US adults, 1988-2018; population-based study","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Public Health"},{"key":"R8-20261015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s43856-026-01405-z","article-title":"HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir","volume":"6","author":"McHantaf","year":"2026","journal-title":"Commun Med (Lond)"},{"key":"R9-20261015","doi-asserted-by":"crossref","first-page":"e181968","DOI":"10.1172\/jci.insight.181968","article-title":"Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates","volume":"9","author":"Webb","year":"2024","journal-title":"JCI Insight"},{"key":"R10-20261015","doi-asserted-by":"crossref","first-page":"106151","DOI":"10.1016\/j.antiviral.2025.106151","article-title":"Tenofovir alafenamide promotes weight gain and impairs fatty acid metabolism-related signaling pathways in visceral fat tissue compared to tenofovir disoproxil fumarate","volume":"237","author":"Dulion","year":"2025","journal-title":"Antiviral Res"},{"key":"R11-20261015","doi-asserted-by":"crossref","first-page":"107288","DOI":"10.1016\/j.vph.2024.107288","article-title":"12-week dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection","volume":"155","author":"Kress","year":"2024","journal-title":"Vascul Pharmacol"},{"key":"R12-20261015","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.3390\/ijms26146546","article-title":"Lipodystrophy in HIV: evolving challenges and unresolved questions","volume":"26","author":"Giralt","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R13-20261015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/QAD.0000000000004131","article-title":"Adipose tissue transcriptome in patients switching efavirenz or a protease inhibitor to raltegravir compared to people without HIV","volume":"39","author":"Hanttu","year":"2025","journal-title":"AIDS"},{"key":"R15-20261015","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkae238","article-title":"Low CD4 counts predict excessive weight gains during first-line treatment for HIV","volume":"79","author":"Hill","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R16-20261015","doi-asserted-by":"crossref","first-page":"101471","DOI":"10.1016\/j.smim.2021.101471","article-title":"Residual immune dysfunction under antiretroviral therapy","volume":"51","author":"Cai","year":"2021","journal-title":"Semin Immunol"},{"key":"R19-20261015","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R21-20261015","doi-asserted-by":"crossref","first-page":"116010","DOI":"10.1016\/j.bcp.2023.116010","article-title":"Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function","volume":"220","author":"Quesada-Lopez","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"R22-20261015","first-page":"e195922","article-title":"A distinct form of fat fibrosis is linked to insulin resistance in people with HIV","volume":"11","author":"Alba","year":"2026","journal-title":"JCI Insight"},{"key":"R23-20261015","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cells11111841","article-title":"Inhibition of adipose tissue beiging by HIV integrase inhibitors, dolutegravir and bictegravir, is associated with adipocyte hypertrophy, hypoxia, elevated fibrosis, and insulin resistance in simian adipose tissue and human adipocytes","volume":"11","author":"Ngono Ayissi","year":"2022","journal-title":"Cells"},{"key":"R24-20261015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QAD.0000000000003455","article-title":"Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model","volume":"37","author":"Perna","year":"2023","journal-title":"AIDS"},{"key":"R25-20261015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/infdis\/jiac175","article-title":"Dolutegravir suppresses thermogenesis via disrupting uncoupling protein 1 expression and mitochondrial function in brown\/beige adipocytes in preclinical models","volume":"226","author":"Jung","year":"2022","journal-title":"J Infect Dis"},{"key":"R26-20261015","doi-asserted-by":"crossref","first-page":"118831","DOI":"10.1016\/j.biopha.2025.118831","article-title":"Differential adipose tissue remodeling and metabolic effects of dolutegravir and bictegravir: implications for HIV therapy","volume":"193","author":"Gisbert-Ferrandiz","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"R27-20261015","doi-asserted-by":"crossref","first-page":"e26268","DOI":"10.1002\/jia2.26268","article-title":"Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa","volume":"27","author":"Manne-Goehler","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"R29-20261015","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1093\/infdis\/jiae532","article-title":"The primacy of adipose tissue gene expression and plasma lipidome in cardiometabolic disease in persons with HIV","volume":"231","author":"Bailin","year":"2025","journal-title":"J Infect Dis"},{"key":"R30-20261015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1210\/clinem\/dgae369","article-title":"Single-cell analysis of subcutaneous fat reveals profibrotic cells that correlate with visceral adiposity in HIV","volume":"110","author":"Bailin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-20261015","doi-asserted-by":"crossref","first-page":"1152003","DOI":"10.3389\/fimmu.2023.1152003","article-title":"Changes in subcutaneous white adipose tissue cellular composition and molecular programs underlie glucose intolerance in persons with HIV","volume":"14","author":"Bailin","year":"2023","journal-title":"Front Immunol"},{"key":"R39-20261015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-8587(24)00150-5","article-title":"Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised double-blind, placebo-controlled phase 2b single-centre clinical trial","volume":"12","author":"Eckard","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R41-20261015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/QAD.0000000000003791","article-title":"Weight loss associated with semaglutide treatment among people with HIV","volume":"38","author":"Haidar","year":"2024","journal-title":"AIDS"},{"key":"R42-20261015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/cid\/ciae151","article-title":"Glucagon-like peptide 1 receptor agonists promote weight loss among people with HIV","volume":"79","author":"Nguyen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R43-20261015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ando.2024.05.008","article-title":"How does bariatric surgery remodel adipose tissue?","volume":"85","author":"Lecoutre","year":"2024","journal-title":"Ann Endocrinol (Paris)"}],"container-title":["Current Opinion in HIV and AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COH.0000000000001069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:00:18Z","timestamp":1792062018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/COH.0000000000001069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/coh.0000000000001069","relation":{},"ISSN":["1746-630X","1746-6318"],"issn-type":[{"value":"1746-630X","type":"print"},{"value":"1746-6318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}